The role of genetic factors in clopidogrel antiplatelet therapy

Cieślewicz, Artur Robert; Kaźmierczak, Ewa; Jabłecka, Anna
April 2012
Advances in Interventional Cardiology;2012, Vol. 8 Issue 2, p126
Academic Journal
Thienopyridine derivative antiplatelet agents play an important role in the treatment of coronary artery disease. Clopidogrel is a drug blocking action of the platelet ADP receptor (P2Y12). It is applied in the form of a prodrug that requires metabolic activation by cytochrome P450 enzymes. The standard antiplatelet therapy in patients with acute coronary syndrome is based on simultaneous administration of clopidogrel and aspirin. Numerous scientific reports indicate that a diverse response to clopidogrel therapy is observed in as many as 25% of patients with acute coronary syndrome. This variation may be caused by genetic factors. Polymorphisms in CYP2C19 (one of the cytochrome P450 enzymes) and ABCB1 (gene coding P-glycoprotein which takes part in absorption of clopidogrel) are considered the most frequent genetic causes of resistance to clopidogrel therapy. Knowledge of these genotypes can be helpful in finding the patients vulnerable to less effective clopidogrel therapy and establishing an effective dose of the drug.


Related Articles

  • Ticagrelor provides improved survival, similar QOL in ACS.  // PharmacoEconomics & Outcomes News;7/1/2013, Issue 682, p10 

    The article discusses a research on the treatment of acute coronary syndromes, in reference to the study "Health-Related Quality of Life of Ticagrelor versus Clopidogrel in Patients with Acute Coronary Syndromes-Results from the PLATO Trial," by L. A. Levin, et al, in the June 2013 issue of...

  • Inhibitori receptora P2Y12 u liječenju koronarne bolesti srca -- izazovi i perspektiva u optimizaciji antitrombocitnog liječenja. Samardžić, Jure // Cardiologia Croatica;Sep/Oct2014, Vol. 9 Issue 9/10, p346 

    Antiplatelet drugs have a fundamental role in acute and chronic pharmacotherapy of coronary artery disease (CAD) as they reduce the risk of ischemic cardiac and cerebrovascular events. Clopidogrel is the most used P2Y12 receptor inhibitor despite it's very variable effect caused by different...

  • Prescribing antiplatelets. Morris, David // Independent Nurse;1/15/2010, p1 

    The article focuses on the prescription of oral antiplatelet agents, aspirin, clopidogrel, and prasugrel, for treating cardiovascular disease (CVD). It recommends the use of low dose aspirin along with a proton pump inhibitor (PPI) and states that even though clopidogrel is little more effective...

  • Bedside Monitoring to Adjust Antiplatelet Therapy for Coronary Stenting. Collet, Jean-Philippe; Cuisset, Thomas; Rang�, Gr�goire; Cayla, Guillaume; Elhadad, Simon; Pouillot, Christophe; Henry, Patrick; Motreff, Pascal; Carri�, Didier; Boueri, Ziad; Belle, Loic; Van Belle, Eric; Rousseau, H�l�ne; Aubry, Pierre; Mons�gu, Jacques; Sabouret, Pierre; O'Connor, Stephen A.; Abtan, J�r�mie; Kerneis, Mathieu; Saint-Etienne, Christophe // New England Journal of Medicine;11/29/2012, Vol. 367 Issue 22, p2100 

    Background: Patients' responses to oral antiplatelet therapy are subject to variation. Bedside monitoring offers the opportunity to improve outcomes after coronary stenting by individualizing therapy. Methods: We randomly assigned 2440 patients scheduled for coronary stenting at 38 centers to a...

  • Pharmacogenetic approach to clopidogrel resistance: recurrent stent thrombosis in two brother. Minareci, Edibe; Er, Arzu; Minareci, Kenan // Medical Journal of Suleyman Demirel University;2014, Vol. 21 Issue 2, p58 

    Clopidogrel, is the antiplatelet treatment choice for prevention of thrombosis after coronary stent implantation. However, despite the use of clopidogrel, a considerable number of patients continue to have stent thrombosis. There is a growing degree of evidence that recurrence of ischemic...

  • FFR-Guided PCI vs Medical Therapy in Stable Coronary Artery Disease. Boyle, Andrew J. // Clinical Cardiology Alert;Oct2012, Vol. 31 Issue 10, p73 

    The author comments on a study by De Bruyne and colleagues that tests the hypothesis that fractional flow reserve (FFR)-guided percutaneous coronary intervention (PCI) in stable coronary artery disease (CAD) will improve outcomes as compared with medical therapy alone. Evidence indicates that...

  • Supplement for Triple Antiplatelet Therapy in Obese Patients Undergoing Stent Implantation. Gao, Wen; Zhang, Qinghua; Ge, Hailong; Guo, Yonghe; Zhou, Zhiming // Angiology;Oct2013, Vol. 64 Issue 7, p561 

    A letter to the editor is presented in response to the article "Triple antiplatelet therapy in obese patients undergoing stent implantation" by S. Balta and colleagues in the March 11, 2013 issue.

  • Effectiveness of cilostazol in transient ischemic attack refractory to aspirin: A report of two cases. GAOPING LIN; DONGDONG REN; SHUNYUAN GUO; YU GENG // Experimental & Therapeutic Medicine;2014, Vol. 7 Issue 3, p739 

    Transient ischemic attack (TIA) is a warning of impending ischemic stroke. It provides an important therapeutic time window in which appropriate intervention may prevent permanent neurological injury. The anti-platelet agent, aspirin, is an option for reducing the risk of stroke following TIA....

  • New Clinical Advisory Issued by National Institute of Neurological Disorders and Stroke (NINDS).  // NLM Technical Bulletin;Sep2011, Issue 382, p11 

    The article offers information on the new clinical advisory by the National Institute of Neurological Disorders and Stroke (NINDS). It states that NINDS stopped the combination antiplatelet therapy for Secondary Prevention of Small Subcortical Strokes (SPS3) with randomized clinical trial in...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics